EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Vectored Immunoprophylaxis for Mucosal Immunity: Advances and Challenges Associated with Recombinant Secretory IgA Expression

Benjamin J Manchester, Jennifer L Gommerman, Shayan Sharif, Leonardo Susta iD, Sarah K Wootton iD

Vaccines · 12.08.2026 · 14 (8) · 692

DOI: 10.3390/vaccines14080692 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 12.08.2026. Verfasst von Benjamin J Manchester und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada. Die Arbeit nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Canada, Natural Sciences and Engineering Research Council of Canada, OVC MSc and PhD Scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Existing vectored immunoprophylaxis (VIP) approaches have primarily focused on IgG, which provides systemic protection but is less specialized in mucosal immunity. In contrast, secretory IgA (sIgA) plays a central role at epithelial surfaces, promoting pathogen neutralization while limiting inflammation. Although monoclonal IgA therapies are effective, their short half-life requires repeated dosing. Thus, VIP strategies enabling sustained sIgA expression at mucosal sites could transform mucosal infection prevention and treatment. This review outlines the key challenges associated with in vivo IgA expression and discusses critical considerations for VIP-mediated IgA delivery at mucosal surfaces, with emphasis on its potential for clinical translation. We provide a detailed overview of platforms for targeted IgA expression, including adeno-associated virus (AAV), adenoviral and lentiviral vectors, and lipid nanoparticle-based systems, alongside relevant routes of administration. Additionally, we examine emerging strategies to enhance the robustness, durability, and localization of IgA expression in vivo. Overall, VIP-enabled IgA expression represents an emerging strategy for enhancing mucosal immunity, with continued advances required to establish its role in the prevention and treatment of mucosal infections.

Schlagwörter

Stichwörter der Autor:innen

adeno-associated virus (AAV)antibody engineeringmonoclonal antibodymucosal immunitysecretory IgAvectored immunoprophylaxis

Autor:innen und Institutionen

  • Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
  • Department of Immunology, Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.

ORCID-Profile: Leonardo Susta, Sarah K Wootton

Förderung

  • Cystic Fibrosis Canada
  • Natural Sciences and Engineering Research Council of Canada
  • OVC MSc and PhD Scholarship
  • Ontario Graduate Scholarship

Zitieren

APA

Manchester, B. J., Gommerman, J. L., Sharif, S., Susta, L., & Wootton, S. K. (2026). Vectored Immunoprophylaxis for Mucosal Immunity: Advances and Challenges Associated with Recombinant Secretory IgA Expression. Vaccines, 14(8), 692. https://doi.org/10.3390/vaccines14080692

Vancouver

Manchester BJ, Gommerman JL, Sharif S, Susta L, Wootton SK. Vectored Immunoprophylaxis for Mucosal Immunity: Advances and Challenges Associated with Recombinant Secretory IgA Expression. Vaccines. 2026;14(8):692. doi:10.3390/vaccines14080692

BibTeX
@article{Manchester2026,
  author = {Manchester, Benjamin J and Gommerman, Jennifer L and Sharif, Shayan and Susta, Leonardo and Wootton, Sarah K},
  title = {Vectored Immunoprophylaxis for Mucosal Immunity: Advances and Challenges Associated with Recombinant Secretory IgA Expression},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {8},
  pages = {692},
  doi = {10.3390/vaccines14080692}
}
Kostenlos starten →